Formula information collection
This article was originally published in The Tan Sheet
Executive Summary
FDA receives the Office of Management and Budget's clearance for its "Infant Formula Requirements" collection of information, the agency says June 21. In the supporting statement it submitted to OMB, FDA says executing regulatory control over the formulation and production of infant formula requires assuring that each batch of a manufacturer's formula is uniform in composition and conforms to known nutrient requirements. In an additional effort to detect noncompliance with formula manufacturing regulations, the information collection is needed to determine whether unauthorized reformulations have occurred. OMB approved the information collection for use through June 2010...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.